Acute myeloid leukemia driven by tandem duplications within the UBTF gene (UBTF-TD AML) is a high-risk pediatric cancer in urgent need of novel therapeutic options. To better understand this disease ...

First-line ibrutinib (Imbruvica) plus venetoclax (Venclexta) led to high response and survival rates in patients with chronic lymphocytic leukemia (CLL) whether or not their cancer harbored high-risk ...

A research team from the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed), has developed a novel combination therapy that ...

The addition of an off-the-shelf pooled stem cell product to a single unit of umbilical cord blood conferred favorable ...

Please provide your email address to receive an email when new articles are posted on . A phase 1 trial is testing a novel CAR-T that targets both ADGRE2 and CLL-1 in adults with AML. The CAR-T is ...

Scientists from the Children’s Hospital of Philadelphia (CHOP) report that they have discovered the underlying biology that identifies a subset of patients with acute lymphoblastic leukemia who have a ...

APOLLO: Optimizing the Treatment of High-Risk Acute Promyelocytic Leukemia With All-Trans Retinoic Acid and Arsenic Trioxide While Minimizing the Role of Chemotherapy The following represents ...

BM -Bone Marrow; WBC max- Maximum WBC before starting venetoclax; CAD-Coronary Artery Disease; RHD- Rheumatic Heart Disease; HCR-Hematological Complete Response. This is an ASCO Meeting Abstract from ...

Combining all-trans retinoic acid (ATRA) with arsenic trioxide (ATO) and idarubicin significantly improved event-free survival (EFS) compared with the standard treatment of ATRA and ...